Aegerion Pharmaceuticals (AEGR +6.5%) trades higher after Deutsche Bank reiterates Buy rating...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion Pharmaceuticals (AEGR +6.5%) trades higher after Deutsche Bank reiterates Buy rating and raises price target to $52 from $41. DB says AEGR is on track to beat guidance of 250-300 patients using Juxtapid its recently-approved treatment for a rare genetic disorder — by the end of the year.